Division of RI Application, Korea Institute of Radiological and Medical Sciences, 75 Nowon-Gil, Gongneung-Dong, Nowon-Gu, Seoul, 01812, Korea.
Radiological and Medico-Oncological Sciences, University of Science and Technology (UST), Seoul, 01812, Korea.
Sci Rep. 2021 Dec 22;11(1):24397. doi: 10.1038/s41598-021-03921-5.
Angiotensin-converting enzyme 2 (ACE2) is an important factor in coronavirus disease (COVID-19) interactions. Losartan (LOS) belongs to the angiotensin receptor blocker (ARB) family. Additionally, the protective role of ACE2 restored by LOS has been suggested and clinically examined in the treatment of COVID-19 patients. Furthermore, clinical trials with LOS have been conducted. However, the mechanism through which LOS enhances ACE2 expression remains unclear. In addition, the response of ACE2 to LOS differs among patients. Our LOS-treated patient data revealed a correlated mechanism of ACE2 with components of the renin-angiotensinogen system. We observed a significant positive regulation of MAS1 and ACE2 expression. In the context of LOS treatment of COVID-19, ACE2 expression could depend on LOS regulated MAS1. Thus, MAS1 expression could predict the COVID-19 treatment response of LOS.
血管紧张素转换酶 2（ACE2）是冠状病毒病（COVID-19）相互作用的重要因素。氯沙坦（LOS）属于血管紧张素受体阻滞剂（ARB）家族。此外，已经在 COVID-19 患者的治疗中提出并临床检查了由 LOS 恢复的 ACE2 的保护作用。此外，已经进行了 LOS 的临床试验。然而，LOS 增强 ACE2 表达的机制尚不清楚。此外，ACE2 对 LOS 的反应在患者之间存在差异。我们的 LOS 治疗患者数据揭示了 ACE2 与肾素-血管紧张素原系统成分之间的相关机制。我们观察到 MAS1 和 ACE2 表达的显著正向调节。在 COVID-19 的 LOS 治疗背景下，ACE2 的表达可能取决于 LOS 调节的 MAS1。因此，MAS1 表达可以预测 LOS 治疗 COVID-19 的反应。
